TEL AVIV, Israel, March 31, 2016 -- Elbit Imaging Ltd. ("EI" or the "Company") (TASE:EMITF) (NASDAQ:EMITF) announced today, the appointment of Mr. Doron Moshe, as the Company's Chief Executive Officer (CEO).
Mr. Moshe's terms of office and employment as the Company’s CEO were approved at the Extraordinary general meeting of the Company's shareholders held on March 31, 2016.
Mr. Moshe served as the Company's CFO since 2010 and as the Company's acting CEO since April 1, 2015 and will continue to serve as the Company's CFO in addition and in parallel to his role as the Company's CEO.
Such appointment is effective as of April 1, 2016.
About Elbit Imaging Ltd.
Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial centers - initiation, construction, and sale of commercial centers and other mixed-use property projects, predominantly in the retail sector, located in Central and Eastern Europe. In certain circumstances and depending on market conditions, the Group operates and manages commercial centers prior to their sale. (ii) Hotels - hotels operation and management. (iii) Medical industries and devices - (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment, and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. (iv) Plots in India - plots designated for sale initially designated to residential projects.
Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as “believe,” “expect,” “intend,” “estimate” and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, a change in market conditions, a decision to deploy the cash for other business opportunities and the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2014, under the caption “Risk Factors.” Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained in our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.
For Further Information: Company Contact Ron Hadassi Chairman of the Board of Directors Tel: +972-3-608-6048 Fax: +972-3-608-6050 [email protected]


Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 



